|
Hyperbiliverdinemia
|
0.610 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Hyperbiliverdinemia
|
0.610 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Cholestasis
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|
|
Cholelithiasis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Decreased liver function
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Green urine
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Hyperbiliverdinemia
|
0.610 |
GeneticVariation
|
disease |
BEFREE |
Hyperbiliverdinaemia (green jaundice) with green plasma and urine may be caused by a genetic defect in the BVR-A gene in conjunction with decompensated liver cirrhosis.
|
19580635 |
2009 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
BLVRA mRNA levels in the liver as well as in PBL are significantly higher in HCC patients most likely as a feedback mechanism to control increased oxidative stress associated with HCC progression.
|
27740521 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Biliverdin reductase-A impairment links brain insulin resistance with increased Aβ production in an animal model of aging: Implications for Alzheimer disease.
|
29981845 |
2018 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease.
|
30073505 |
2019 |
|
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to the controls, substantially increased BLVRA expression was detected in PBL (p<0.001) of therapeutically naïve HCV patients. mRNA levels of BLVRA in PBL closely correlated with those in liver tissue (r2 = 0.347,p = 0.03).
|
23536765 |
2013 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Consequently, not just the increased levels of biliverdin reductase-A, but also its changed activity and phosphorylation state, should be taken into account when considering potential biomarkers for Alzheimer disease and mild cognitive impairment.
|
21241799 |
2011 |
|
Mild cognitive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Consequently, not just the increased levels of biliverdin reductase-A, but also its changed activity and phosphorylation state, should be taken into account when considering potential biomarkers for Alzheimer disease and mild cognitive impairment.
|
21241799 |
2011 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four significant associations with CAD were detected after controlling age and the false discovery rate at 15%: the recessive effect of SNP rs887829 (UGT1A1 G-364A) [age-adjusted odds ratio (OR): 0.24; 95% confidence interval (CI): 0.10-0.60; P=0.0014] and dominant effect of rs4149013 (SLCO1B1 A-12099G) (age-adjusted OR: 0.70; 95% CI: 0.55-0.91; P=0.0069) on male CAD, and the additive effects of rs2877262 (BLVRA G+1238/in6C) (age-adjusted OR: 0.73; 95% CI: 0.59-0.89; P=0.0021) and rs2690381 (BLVRA G+2613/in6A) (age-adjusted OR: 0.70; 95% CI: 0.56-0.86; P=0.0008) on female CAD.
|
19238116 |
2009 |
|
Liver Cirrhosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
FOXD2-AS1/miR-139-5p/BLVRA or CYTH2 axis might be the underlying molecular mechanism that dissects HCC development caused by cirrhosis.
|
31758243 |
2020 |
|
Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
FOXD2-AS1/miR-139-5p/BLVRA or CYTH2 axis might be the underlying molecular mechanism that dissects HCC development caused by cirrhosis.
|
31758243 |
2020 |
|
Liver Cirrhosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Hyperbiliverdinaemia (green jaundice) with green plasma and urine may be caused by a genetic defect in the BVR-A gene in conjunction with decompensated liver cirrhosis.
|
19580635 |
2009 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, nitrosative stress-induced modifications on hippocampal BVR-A are an early event in the pathogenesis of AD since they appear also in MCI subjects and could contribute to the antioxidant and metabolic derangement characteristic of these neurodegenerative disorders.
|
21483094 |
2011 |
|
Mild cognitive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, nitrosative stress-induced modifications on hippocampal BVR-A are an early event in the pathogenesis of AD since they appear also in MCI subjects and could contribute to the antioxidant and metabolic derangement characteristic of these neurodegenerative disorders.
|
21483094 |
2011 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, nitrosative stress-induced modifications on hippocampal BVR-A are an early event in the pathogenesis of AD since they appear also in MCI subjects and could contribute to the antioxidant and metabolic derangement characteristic of these neurodegenerative disorders.
|
21483094 |
2011 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrate a critical role for BVRA in protecting against lipid accumulation and oxidative stress in hepatocytes, which may serve as a future therapeutic target for NAFLD and its progression to NASH.
|
31422074 |
2019 |
|
Fatty Liver Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrate a critical role for BVRA in protecting against lipid accumulation and oxidative stress in hepatocytes, which may serve as a future therapeutic target for NAFLD and its progression to NASH.
|
31422074 |
2019 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, the BVRA positive macrophage is a source of anti-inflammatory cytokine IL-10 in injured kidney, which may provide a potential target for treatment of kidney disease.
|
26393580 |
2015 |
|
Pulmonary Emphysema
|
0.010 |
Biomarker
|
disease |
BEFREE |
In particular, x-ray computed tomography (CT) emphysema measurements are used to identify the most diseased and the second-most diseased lobes as BLVR targets.
|
29051040 |
2018 |
|
Fatty Liver Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In vitro studies have demonstrated that BVR-A is a substrate of the insulin receptor and regulates IRS1 by avoiding its aberrant activation, and in animal model of obesity the loss of hepatic BVR-A has been associated with glucose/insulin alterations and fatty liver disease.However, no studies exist in humans.
|
30826467 |
2019 |